SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (2888)11/28/2011 6:57:32 PM
From: Rocky92 Recommendations  Read Replies (1) | Respond to of 3027
 
" I doubt that SNY’s AG has actually been withdrawn from the market."

You can "doubt" the "withdrawal" all you want. If a judge says that sales have been "suspended," I will take that at face value. The fact the the AG is not looking for new accounts is what is important, not that there may be sales being made under prior contractual obligations.

That fact that there are probably ongoing sales surely means that the new "hybrid" profit sharing will continue. It would be very hard for MNTA to argue otherwise, and I don't agree that NVS is somehow "screwing" MNTA. A contract is a contract and MNTA is still going to do pretty darn well. JMO.



To: DewDiligence_on_SI who wrote (2888)11/28/2011 8:47:26 PM
From: IRWIN JAMES FRANKEL2 Recommendations  Read Replies (1) | Respond to of 3027
 
Of course I read it. Did you read the order? I did. I also appreciate the duty of an attorney not to mislead the court.

But when the court cites representations of MNTA/Sandoz to the effect that "sales of the authorized generic have been suspended", I accept it at face value.


ij





HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News